1.Clinical application characteristics of distraction osteogenesis implants
Chinese Journal of Tissue Engineering Research 2009;13(39):7755-7758
OBJECTIVE: To investigate the progress of clinical application of implant during distraction osteogenesis in the jaw bones, and to evaluate its biocompatibility.METHODS: The first author retrieved CNKI database from 1989 to 2009 in Chinese and Medline database from 1989 to 2009 in English with the key words of "jaw, distraction osteogenesis, treatment". A total of 56 articles were screened according to inclusion and exclusion criteria. Finally, 20 articles concerning treatment progress of distraction osteogenesis and clinical application of implant were included.RESULTS: Distraction osteogenesis implants contained intraoral or extraoral distraction device, which could be used for distraction of transport plate. A distraction was selected in accordance with patients' condition and requirement. Distraction osteogenesis had been an important manner for complicated tooth jaw facial deformity and jaw defect in oral dentofacial surgery and Orthodontic treatment. It could have effective osteogenesis in combination with various systemic therapy, local therapy and physical therapy. Presently, distraction osteogenesis implants were metal materials. Metal implants have great advantages in preventing bacterium growth, keeping implant fixation and distraction effects, and the price was high. However, the cost of Ni-Ti memory alloy wire was lower compared with common retractors. The fixing device and alloy wire closely adhered to the bone could be completely implanted into tissues, with the advantages of anti-infection and completely closing the exterior and interior wound. CONCLUSION: Distraction osteogenesis is a new method for treating dental and craniofacial hypodevelopment straightening of teeth and for repairing jaw bone defect deformation. Biocompatibility of metal implants was good such as internal small Ni-Ti memory alloy wire. The biocompatibility of other types of implants should be improved.
3.An experimental study on the role of MSCs in inducing regulatory B cells and the underlying mechanisms
Chinese Journal of Organ Transplantation 2013;34(7):428-431
Objective To observe the immunoregulatory roles of MSCs in inducing proliferation of B regulatory cells (Bregs).Method DA Rat MSCs were co-cultured with Wistar rat B cells.The levels of IL-10 and secrete proinflammatory cytokines in the supematants were determined by using ELISA.The proliferation and apoptosis of B cells after interaction with MSCs were analyzed by using FACS.In order to investigate whether Bregs are involved in the phagocytosis of immune complex (IC),B cells and Bregs were incubated with FITC-OVA-IC.The fluorescence intensity was detected by using immunofluorescence microscopy.Results MSCs induced B cells to differentiate into Bregs with high CD19,CD1d and CD5 expression and high IL-10 level.The proliferation of B cells was significantly suppressed after interaction with MSCs.Bregs had enhanced phagocytic capacity as compared with that of B cells.Bregs significantly inhibited maDC-induced CD4+ T cell proliferation compared to B cells,without depressing IL-2 or IFN-γ secretion.Conclusion MSCs induce freshly isolated B cells to differentiate into Bregs characterized by the ability to preferentially produce IL-10.
4.A novel HER2-targeted drug:T-DM1 antibody-drug conjugate
Chinese Journal of Clinical Oncology 2013;(19):1203-1206
T-DM1 is a novel antibody-drug conjugate that has similar biological activity with that of trastuzumab. T-DM1 specifically delivers DM1, the effective anti-microtubule drug, into the cytoplasm of tumor cells with HER2 overexpression. The efficacy of T-DM1 monotherapy is better than lapatinib in combination with capecitabine and T-DM and is expected to become the standard second-line treatment for HER2-positive advanced breast cancer drugs. Clinical trials that compare T-DM1 with trastuzumab joint taxane as the first-line of treatment for advanced breast cancer trials are currently being performed. T-DM1 is a brand new anti-HER2 drug after trastuzumab. U.S. FDA already approved T-DM1 as a drug for the treatment of HER2-positive advanced breast cancer patients.
5.Maternal and Perinatal Morbidity after 40 weeks and Postdate Pregnancy
Journal of Shanghai Jiaotong University(Medical Science) 2006;0(02):-
Objective To analyse the maternal and perinatal morbidity after 40 weeks and postdate pregnancy,and to research suitable time of labor induction. Methods Clinical data of 357 pregnant women after 40 weeks with normal menstrual period were analysed.They were divided into four groups according to the different weeks of gestation. Results There were no significant difference in the four groups for maternal and perinatal morbidity,the rate of spontaneons labor,the degree of cervical repine and the successful rate of labor induction.The successful rate of artificial rupture of membranes was higher in the groups with Bishop score ≥6(P
8.To explore "the relief time" of diseases involving the six meridians in Shang Han Lun in light of the sequence of three yin and three yang
Xiaoqiang YUE ; Xue YANG ; Jian CUI
Journal of Integrative Medicine 2008;6(2):124-7
The time of six meridians diseases tending to be cured in Shang Han Lun (Treatise on Cold Diseases) is always one of the key points for study, but up till now no satisfied explanations are made. The authors try to study it on the basis of the theory of "three-yin and three-yang" according to the relationship between human body and the environment.
9.Comparative study on anterior cervical surgery by microendoscopic and open operation
Jian WANG ; Yue ZHOU ; Tongwei CHU
Orthopedic Journal of China 2006;0(05):-
[Objective]To complete comparison between anterior cervical surgery by microendoscopic and open operation,explore feasibility and efficacy of anterior cervical decompression,interbody fusion and fixation by microendoscopic surgery,and give preliminary clinical evaluation of mieroendoscopic surgery.[Method]In a retrospective study,46 patients underwent one level cervical surgery by anterior approach.23 patients(23~64 years,41.5 years in average)were treated with microendoscopic surgery as microendoscopic group.Under general anesthesia,a transverse incision(1.6 cm)was made at right side of neck.A tubular retractor was then inserted and fixed,and a specially designed endoscope was placed inside the tubular retractor.Discectomy and interbody fusion with insertion of Cage or/and plate fixation was performed by endoscope.At fracture and dislocation patient group,titanium Cage was used in 1 case,CBK in 1 case,plate in 5 cases.At cervical disc herniation patient group,titanium Cage was used in 2 cases,CBK in 12 cases,plate in 2 cases.During the same period,23 patients(25~68 years,46.5 years in average)were treated with open surgery as open group.A transverse incision(4~5 cm)was made by right route approach.Discectomy and interbody fusion with Cage or/and plate fixation was performed by general procedure.[Result]At microendoscopic group,23 cases were followed up from 10 to 22 months(16.5 months in average),and mean operative time were 95 minutes,mean blood loss 90 ml.For fracture and dislocation patients,by Frankels classification,2 cases with complete tetraplegia showed no improvement,2 cases with incomplete tetraplegia improved from grade C to grade D postoperatively,1 case upgraded from C to E.For cervical spondylotic myelopathy patients with disc herniation,according to Odoms scoring system,10 cases had excellent outcome,5 good,1 fair.At open group,23 cases were followed up from 8~21 months(15.2 months as average),and mean operative time was 95 minutes,mean blood loss 90 ml.By Frankels classification,2 cases with complete tetraplegia had no improvement,3 cases with incomplete tetraplegia improved from C to D,1 case from D to E.According to Odoms scoring system,8 patients suffering from cervical spondylotic myelopathy with disc herniation had excellent result,6 good,2 fair.[Conclusion]Compared with open surgery,microendoscopic surgery with endoscopic instrument and technique can be used for one level discectomy,interbody fusion and internal fixation,and offer a similar short-term good clinical outcome with minimal incision,less traumatic reaction and postoperative discomfort.
10.Clinical application of unilateral decompression,interbody fusion and pedicle screw fixation under endoscopic system
Jian WANG ; Yue ZHOU ; Tongwei CHU
Orthopedic Journal of China 2006;0(19):-
[Objective]To explore the feasibility and efficiency of treatment of lumbar degenerative disease with unilateral decompression,interbody fusion and percutaneous pedicle screw fixation under endoscopic system.[Method]From June 2004 to March 2007,20 patients underwent minimally invasive transforaminal lumbar interbody fusion(TLIF) or posterior lumbar interbody interbody fusion(PLIF),which consisted of 11 male and 9 female patients.The mean age was 46.2 years(range,31~70),and the preoperative diagnosis consisted of postoperative recurrent lumbar disc herniation(n =8),far lateral lumbar disc herniation(n =4),spinal stenosis(n = 3),lumbar instability(n = 3),and discogenic lumbar pain(n =2).One-level decompression and intebody fusion with unilateral pedicle screw fixation under endoscopic system was performed in all of cases(12 at L4、5,and 8 at L5S1).A paramedian,muscle-sparing approach was performed through a tubular retractor docked unilaterally on the facet joint.A total facetectomy was then conducted,exposing and removing the disc(TLIF),or microendoscopic discectomy(MED) was performed(PLIF).The intervertebral space preparation were completed through the X-tube or METRx system.Interbody fusion was achieved with autograft bone and interbody cages.Unilateral pedicle screw-rod placement was accomplished.[Result]There was no conversions to open surgery.Operative time averaged 115 minutes(range,100~165 min).Blood loss averaged 130 ml(range,50~180 ml).Mean length of postoperative hospital stay was 11 days(range,7~15 days).All patients presenting with preoperative low back pain and /or lower extremity radicular pain(n= 20) had resolution of symptoms postoperatively.Complications included two cases of new radiculopathy postoperatively(one from graft dislodgement,the other from hematoma formation).Twenty patients were followed up 10~39 months(average 21.6 months).The preoperative,1 month postoperative and last follow-up Oswestry Disability Index(ODI scores were 42.05+8.36,21.33?6.37 and 12.31?3.75 separately(P